ARWR Logo

Arrowhead Pharmaceuticals, Inc. (ARWR) 

NASDAQ
Market Cap
$2.28B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
250 of 774
Rank in Industry
145 of 432

Largest Insider Buys in Sector

ARWR Stock Price History Chart

ARWR Stock Performance

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in …

Insider Activity of Arrowhead Pharmaceuticals, Inc.

Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $82,990 and sold $8.56M worth of Arrowhead Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $103,722 and sold $24.69M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lu Hongbo (director) — $165,980.

The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.

List of Insider Buy and Sell Transactions, Arrowhead Pharmaceuticals, Inc.

2024-07-02SaleChief Commercial Officer
9,394
0.0073%
$25.28$237,4800.00%
2024-05-02Saledirector
1,799
0.0014%
$23.31$41,935-2.20%
2024-04-01SaleChief Discovery/Trans Medicine
6,000
0.0048%
$28.03$168,180-15.79%
2024-03-20Purchasedirector
1,000
0.0008%
$27.50$27,500-15.06%
2024-03-19Purchasedirector
1,000
0.0008%
$28.00$28,000-13.77%
2024-03-18Purchasedirector
1,000
0.0008%
$27.49$27,490-14.94%
2024-03-06SaleChief Financial Officer
40,000
0.0323%
$35.19$1.41M-32.28%
2024-01-31SaleChief Executive Officer
57,499
0.0525%
$32.35$1.86M-22.99%
2024-01-12SaleChief Discovery/Trans Medicine
7,940
0.0075%
$36.89$292,904-31.55%
2024-01-11Saledirector
2,911
0.0028%
$38.06$110,788-33.50%
2024-01-11Saledirector
3,147
0.003%
$38.06$119,787-33.50%
2024-01-11Saledirector
3,934
0.0037%
$38.07$149,759-33.50%
2024-01-11Saledirector
4,720
0.0045%
$38.10$179,813-33.50%
2024-01-05SaleCOO and General Counsel
22,841
0.021%
$35.27$805,716-29.89%
2024-01-05SaleChief Financial Officer
16,104
0.0148%
$35.27$567,910-29.89%
2024-01-05Sale
32,143
0.0295%
$35.18$1.13M-29.89%
2024-01-05SaleChief Medical Officer
8,303
0.0076%
$35.26$292,804-29.89%
2024-01-05SaleChief Commercial Officer
74
<0.0001%
$33.89$2,508-29.89%
2024-01-04SaleCOO and General Counsel
1,600
0.0014%
$32.63$52,208-26.93%
2024-01-03SaleCOO and General Counsel
8,749
0.0082%
$32.28$282,439-20.57%

Insider Historical Profitability

24.46%
Anzalone Christopher RichardChief Executive Officer
3715048
2.9884%
$18.37435<0.0001%
Myszkowski Kenneth AllenChief Financial Officer
400600
0.3222%
$18.37127<0.0001%
GIVEN DOUGLAS Bdirector
129711
0.1043%
$18.37119<0.0001%
Ferrari Maurodirector
60778
0.0489%
$18.3724+71%
Lu Hongbodirector
33680
0.0271%
$18.3730

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$438.91M12.3615.35M+15.36%+$58.43M0.01
The Vanguard Group$354.76M9.9912.4M+16.23%+$49.53M0.01
Avoro Capital Advisors Llc$244.69M6.898.56M+657.13%+$212.37M2.93
State Street$187.64M5.286.56M-3.87%-$7.56M0.01
Fidelity Investments$182.89M5.156.39M+89.68%+$86.47M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.